（1）Yue Shi*, Qi Zhang*, Hai Bi*, Min Lu*, Yezhen Tan, Daojia Zou, Liyuan Ge, Zhigang Chen, Cheng Liu#, Weimin Ci#, Lulin Ma#. Decoding the multicellular ecosystem of vena caval tumor thrombus in clear cell renal cell carcinoma by single-cell RNA sequencing. Genome Biology. 2022; 23(1): 87. (IF 17.906)
（2）Yu Zhang*, Hai Bi*, YunJie Fu, HongXian Zhang, ShuDong Zhang, Ke Liu, Lei Liu, Nan Li, LuLin Ma. Cephalic inferior vena cava non-clamping technique versus standard procedure for robot-assisted laparoscopic level II-III thrombectomy: a prospective cohort study. Int J Surg. (Accepted; IF 13.4)
（3）Qi Zhang*, Yinglu Liang*, Yi Zhang, Zihao Tao, Rui Li#, Hai Bi#. A comparative study of attention mechanism based deep learning methods for bladder tumor segmentation. Int J Med Inform. 2023; 171: 104984.
（4）Yu Zhang*, Hai Bi*, Ye Yan, Zhuo Liu, Guoliang Wang, Yimeng Song, Shudong Zhang#, Cheng Liu#, Lulin Ma#. Comparative analysis of surgical and oncologic outcomes of robotic, laparoscopic and open radical nephrectomy with venous thrombectomy: a propensity-matched cohort study. Int J Clin Oncol. 2023; 28(1): 145-154.
（5）Qais Baheen*, Hai Bi*, Kai Wang, Min Lu, Hongxian Zhang#, Lulin Ma#. Clinical experience and treatment strategy of leiomyosarcoma originating from the renal vein. Eur J Med Res. 2022; 27(1): 100.
（6）Zenan Liu*, Hai Bi*, Wei He, Xuehua Zhu, Jide He, Min Lu, Jian Lu#. Preoperative metabolic syndrome and HDL-C level predict the prognosis of patients following radical cystectomy: a propensity score matching study. Front Oncol. 2022; 12: 833305.
（6）Yu Zhang*, Xiaojun Tian*, Hai Bi*, Peng Hong, Zhuo Liu, Ye Yan, Cheng Liu#, Lulin Ma#. Oncologic outcomes of renal cell carcinoma patients undergoing radical nephrectomy and venous thrombectomy: prospective follow-up from a single center. J Oncol. 2022; 2022: 9191659.
（7）Yu Zhang*, Xiaojun Tian*, Hai Bi*, Ye Yan, Zhuo Liu, Cheng Liu, Shudong Zhang#, Lulin Ma#. Nomogram predicting the progression-free survival of renal cell carcinoma patients with venous thrombus after surgery. Front Oncol. 2022; 12: 765092.
（8）Hai Bi*, Ye Yan*, Dong Wang*, Zijian Qin, Guoliang Wang, Lulin Ma, Yi Huang#, Jian Lu#. Predictive value of preoperative lymphocyte-to-monocyte ratio on survival outcomes in bladder cancer patients after radical cystectomy. J Cancer, 2021; 12(2): 305-315.
（9）Hai Bi*, Jipeng Yin*, Lang Zhou, Yaqian Wu, Liyuan Ge, Min Lu, Lei Liu, Hongxian Zhang, Yongzhe Zhao#, Cheng Liu#, Lulin Ma#. Clinicopathological and prognostic impact of somatic mutations in Chinese patients with clear cell renal cell carcinoma. Transl Androl Urol, 2020; 9(6): 2751-2763.
（10）Guoliang Wang*, Hai Bi*, Jianfei Ye, Hongxian Zhang, Xiaofei Hou, Cheng Liu, Min Qiu, Yu Tian, Dharam Kaushik, Lulin Ma#. Transabdominal approach for renal cell carcinoma with supradiaphragmatic tumor thrombus: description of a modified technique and indications for treatment. J Int Med Res, 2020; 48(11): 300060520962288.
（11）Bi Hai*, Huang Yi, Wang Guoliang, Ma Lulin#, Lu Min#. Impact of body mass index and pretreatment hemoglobin level on prognosis following radical cystectomy for bladder cancer in males and females. Urol Int, 2020; 104(1-2): 28-35.
（12）Hai Bi*, Zhengyang Guo*, Xiao Jia, Huiying Liu, Lulin Ma#, Lixiang Xue#. The key points in the pre-analytical procedures of blood and urine samples in metabolomics studies. Metabolomics, 2020; 16(6): 68.
（13）Hai Bi*, Ya Tian*, Chuan Song*, Jiarui Li, Tingting Liu, Zhen Chen, Chen Chen, Yi Huang#, Yuanyuan Zhang#. Urinary microbiota—a potential biomarker and therapeutic target for bladder cancer. J Med Microbiol, 2019; 68(10): 1471-1478.
（14）Qiyang Shen*, Hai Bi*, Fuhai Yu, Liting Fan, Menliang Zhu, Xiao Jia, Jihong Kang#. Non-targeted metabolomic analysis of skeletal muscle in a dehydroepiandrosterone-induced mouse model of polycystic ovary syndrome. Mol Reprod Dev, 2019; 86(4): 370-378.
（15）Chuang Tian*, Yuanyuan Deng*, Yong Jin, Songshan Shi, Hai Bi#. Long non-coding RNA RNCR3 promotes prostate cancer progression through targeting miR-185-5p. Am J Transl Res, 2018; 10(5): 1562-1570.
毕海*，吴雅倩，强紫阳，刘承，王国良，黄毅，马潞林#。完全机器人辅助腹腔镜回肠原位膀胱构建的手术技巧。中国微创外科杂志。2022; 22(5): 397-402.
毕海*，王皓，彭冉，刘承，马潞林#。保留膀胱治疗后完全机器人辅助腹腔镜根治性膀胱切除术+原位回肠膀胱1例报告。中华泌尿外科杂志。2022； 43(6): 455-457.
毕海*，覃子健，刘承，王国良，石文君，黄毅，马潞林#。淋巴细胞/单核细胞比值对根治性膀胱全切患者生存预后的预测价值。临床泌尿外科杂志。2021; 36(5): 342-347.
毕海*，黄毅#，马潞林，陆敏，张树栋，张洪宪。3例肾尤文肉瘤合并下腔静脉癌栓的诊治。北京大学学报（医学版）。2020; 52(5): 985-989.
覃子建*，毕海#，王国良，陆敏，马潞林。膀胱巢状变异型尿路上皮癌的临床特点分析。中华泌尿外科杂志。2019; 40(6): 440-443.
覃子健*，毕海#，马潞林，黄毅，张帆。肠代膀胱内原发肠源性腺癌1例。北京大学学报（医学版）。2018; 50(4): 737-739.
五、基金项目
国家自然科学基金青年项目，82102975，KIF15/PRMT3/ABCG2轴在前列腺癌多西他赛耐药中的作用和机制研究，2022/1-2024/12，30万，主持；
陕西省重点研发计划-一般项目-社会发展领域，2023-YBSF-051，人工智能辅助膀胱镜在膀胱肿瘤多维度诊断中的应用研究，2023-1-1至2024-12-31，5万，在研，主持；
北京大学第三医院创新转化基金，BYSYZHKC2022104，基于铁蛋白底盘创建顺铂纳米药物递送平台用于膀胱癌靶向膀胱灌注治疗的研究，2023-1-1至2024-12-31，50万，在研，主持；
北京市自然科学基金-海淀原始创新联合基金（前沿项目），19L2037，多模态与混合模态视角下基于结构稀疏性与分层局部性的膀胱镜下肿瘤识别及智能诊断研究，2019/12-2022/12，28万，子课题负责人；
北京大学第三医院人才项目C类，BYSYZD2021043，KIF15对去势抵抗性前列腺癌多西他赛化疗敏感性影响的作用机制研究，2022/1-2024/12，10万，主持；
北京大学第三医院人才孵育基金（青年骨干），BYSYFY2021033，基于深度学习的膀胱镜下肿瘤智能识别与分割研究，2021/07-2024/6，5万，主持；
北大医学青年科技创新培育基金，BMU2020PYB002，前列腺周脂肪组织产生的Resistin在前列腺癌发生发展中的作用及机制探索，2020/1-2020/12，4万，主持。
